Novo Nordisk A/s

This study tests two new drugs, CagriSema and cagrilintide, to help children and adolescents with overweight or obesity lose weight. About 460 participants will receive either the study drugs, a standard drug (semaglutide), or a placebo for up to 4 years and 10 months. The goal i…

This program provides free daily injections of concizumab to people with congenital haemophilia who need better treatment. Participants will be monitored for safety and how well the medicine works over several years. The program is for those with severe haemophilia A or B, with o…

This study looks at how three weight-loss medications—CagriSema, semaglutide, and cagrilintide—affect muscle health in 100 adults aged 50-70 with obesity and slightly high blood sugar. Participants will receive one of the drugs or a placebo for up to 15 months. The goal is to mea…

This study tests whether a new medicine, UBT251, is safe and helps people with overweight or obesity lose weight. About 333 adults will receive either UBT251 or a placebo (dummy pill) by chance. The main goals are to check for side effects and measure weight change over time.

This study tests if a new insulin taken once a week (insulin icodec) controls blood sugar as well as a standard daily insulin (insulin glargine) in adults with type 1 diabetes. About 877 participants will use either weekly or daily insulin, plus rapid-acting insulin at meals, for…

This study tests a new medicine, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults with ATTR-CM will …

This study tests if a once-weekly insulin shot (icodec) works as well as daily insulin shots for controlling blood sugar in people with type 2 diabetes. About 586 adults who have never used insulin before will take either the weekly or a daily insulin for 13 months. The goal is t…

This study tests a new medicine called NNC0487-0111, given as a weekly shot, to see if it helps people with obesity lose weight safely. About 1,150 adults will receive either the active drug or a placebo (dummy shot) for several months. The main goal is to measure how much body w…

This early-stage study looks at whether combining two experimental weight-loss drugs (cagrilintide and NNC0480-0389) causes less nausea, vomiting, and diarrhea than taking cagrilintide alone. About 100 women with overweight or obesity will receive both combinations at different t…